Published in Mol Gen Genet on December 01, 1998
Sld3, which interacts with Cdc45 (Sld4), functions for chromosomal DNA replication in Saccharomyces cerevisiae. EMBO J (2001) 2.70
Regulation of replication timing in fission yeast. EMBO J (2001) 2.49
Dpb11 controls the association between DNA polymerases alpha and epsilon and the autonomously replicating sequence region of budding yeast. Mol Cell Biol (2000) 2.35
A DNA damage-regulated BRCT-containing protein, TopBP1, is required for cell survival. Mol Cell Biol (2002) 2.09
Rad18 is required for DNA repair and checkpoint responses in fission yeast. Mol Biol Cell (1999) 1.98
Schizosaccharomyces pombe cells lacking the amino-terminal catalytic domains of DNA polymerase epsilon are viable but require the DNA damage checkpoint control. Mol Cell Biol (2001) 1.79
Genetic and physical interactions between DPB11 and DDC1 in the yeast DNA damage response pathway. Genetics (2002) 1.66
Systematic deletion analysis of fission yeast protein kinases. Eukaryot Cell (2005) 1.51
Human TopBP1 ensures genome integrity during normal S phase. Mol Cell Biol (2005) 1.31
A single unbranched S-phase DNA damage and replication fork blockage checkpoint pathway. Proc Natl Acad Sci U S A (2002) 1.23
Brc1-mediated DNA repair and damage tolerance. Genetics (2005) 1.18
Regulation of chk1. Cell Div (2009) 1.12
Turning off the G2 DNA damage checkpoint. DNA Repair (Amst) (2007) 0.91
Rad4TopBP1, a scaffold protein, plays separate roles in DNA damage and replication checkpoints and DNA replication. Mol Biol Cell (2006) 0.87
Identification and cloning of two putative subunits of DNA polymerase epsilon in fission yeast. Nucleic Acids Res (2004) 0.84
Initiation of DNA damage responses through XPG-related nucleases. EMBO J (2012) 0.76
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
Ultralong single-wall carbon nanotubes. Nat Mater (2004) 3.83
Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer (1991) 2.98
Phytochelatin synthase genes from Arabidopsis and the yeast Schizosaccharomyces pombe. Plant Cell (1999) 2.74
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med (1986) 2.70
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
Incidence of high blood lead levels in Chicago children. Pediatrics (1969) 2.46
Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst (1999) 2.25
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med (2001) 2.09
Brain metastases from colorectal carcinoma. The long term survivors. Cancer (1996) 2.01
Rad18 is required for DNA repair and checkpoint responses in fission yeast. Mol Biol Cell (1999) 1.98
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Wound recurrence following conventional treatment of colorectal cancer. A rare but perhaps underestimated problem. Dis Colon Rectum (1996) 1.77
Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc Natl Acad Sci U S A (1999) 1.77
Malignant lymphoma of bone. Cancer (1986) 1.66
The G(2) DNA damage checkpoint targets both Wee1 and Cdc25. J Cell Sci (2000) 1.61
Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer (1984) 1.52
Use of human leukocyte-specific monoclonal antibodies for clinically immunophenotyping lymphocytes of rhesus monkeys. Cytometry (1994) 1.51
The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer (1986) 1.50
Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol (2001) 1.42
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene (2001) 1.41
Radiation therapy quality control in a clinical trial of adjuvant postoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys (1995) 1.35
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg (1990) 1.34
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol (1997) 1.31
A single p34cdc2 protein kinase (encoded by nimXcdc2) is required at G1 and G2 in Aspergillus nidulans. J Cell Sci (1994) 1.30
Ambulatory treatment of lead poisoning: report of 1,155 cases. Pediatrics (1970) 1.28
The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol (1992) 1.24
Postoperative follow-up of patients with carcinoma of the colon. Mayo Clin Proc (1983) 1.20
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer (2009) 1.18
The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes. Biochem J (1985) 1.17
Lymphoma in macaques: association with virus of human T lymphotrophic family. Science (1984) 1.15
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med (1979) 1.14
Varying intensity of postremission therapy in acute myeloid leukemia. Blood (1992) 1.13
Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol (1985) 1.13
Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer (1995) 1.12
A homologue of the Rad18 postreplication repair gene is required for DNA damage responses throughout the fission yeast cell cycle. Mol Genet Genomics (2001) 1.12
A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol (2001) 1.12
Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells. Oncogene (1999) 1.11
Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver. Mayo Clin Proc (1985) 1.10
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.09
Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). N Engl J Med (1987) 1.08
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol (1997) 1.07
Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J Urol (1999) 1.05
A NIMA homologue promotes chromatin condensation in fission yeast. J Cell Sci (1998) 1.05
Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med (1987) 1.05
Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (1987) 1.05
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol (1986) 1.03
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med (1992) 1.03
A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer (1991) 1.02
Characterization of pigs transgenic for human decay-accelerating factor. Transplantation (1997) 1.01
Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer (1974) 1.01
Postoperative adjuvant therapy of rectal cancer: an analysis of disease control, survival, and prognostic factors. Int J Radiat Oncol Biol Phys (1989) 1.00
Intraoperative and external beam irradiation for locally advanced colorectal cancer. Ann Surg (1988) 0.98
Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G2 checkpoint. Oncogene (2006) 0.98
Monoclonal antibodies (F36/22 and M7/105) to human breast carcinoma. Cancer Res (1983) 0.97
Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. Dis Colon Rectum (1996) 0.96
Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer (1978) 0.96
Transjugular liver biopsy: assessment of safety and efficacy of the Quick-Core biopsy needle. Abdom Imaging (2002) 0.96
Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU. Int J Radiat Oncol Biol Phys (1997) 0.95
Partial splenectomy for staging Hodgkin's disease: risk of false-negative results. N Engl J Med (1978) 0.95
The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma. Cancer (1987) 0.94
Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Oncol (1984) 0.93
Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol (1988) 0.92
Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst (1989) 0.92
Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol (1995) 0.91
A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma. Int J Radiat Oncol Biol Phys (1982) 0.91
Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol (1992) 0.91
Haemosiderin-like properties of free-radical-modified ferritin. Biochem J (1986) 0.91
Epithelioid granulomas in Hodgkin disease. A favorable prognostic sign? JAMA (1975) 0.90
The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience. J Clin Oncol (1986) 0.90
Rapid reporting and review of an increased incidence of a known adverse event. J Natl Cancer Inst (2000) 0.89
Ensuring the stability of the genome: DNA damage checkpoints. ScientificWorldJournal (2001) 0.89
Radiation-induced generation and properties of lipid hydroperoxide in liposomes. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.89
Low temperature emission spectra of individual single-walled carbon nanotubes: multiplicity of subspecies within single-species nanotube ensembles. Phys Rev Lett (2004) 0.89
Hepatic pathology associated with Hodgkin's disease. Cancer (1974) 0.89
BIMAAPC3, a component of the Aspergillus anaphase promoting complex/cyclosome, is required for a G2 checkpoint blocking entry into mitosis in the absence of NIMA function. J Cell Sci (1998) 0.89
Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol (1998) 0.89
Prognostic significance of mediastinal mass in adult Hodgkin's disease. Cancer (1984) 0.88
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma. Clin Pharmacol Ther (1976) 0.87
Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs (1991) 0.86
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials. Cancer Treat Rep (1986) 0.86
Failure of the urinary delta-aminolevulinic acid test to detect pediatric lead poisoning. Am J Clin Pathol (1970) 0.86
New adjuvant therapy for colon cancer: justified hope or commercial hype. Surg Oncol Clin N Am (2000) 0.85
Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med (1978) 0.85
Current issues in the treatment of colorectal cancer. Crit Rev Oncol Hematol (1986) 0.85
Primary lymphoma of the testis. Int J Radiat Oncol Biol Phys (1982) 0.85
Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. Leukemia (1992) 0.84
Postoperative screening of patients with carcinoma of the colon. Dis Colon Rectum (1982) 0.84
Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. J Natl Cancer Inst (1997) 0.83
Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer (1993) 0.83
Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated? Lancet (1984) 0.83
Isolation and characterization of the Pin1/Ess1p homologue in Schizosaccharomyces pombe. J Cell Sci (2001) 0.83